Medical Licensing (MD/DO) · Independent exam preparation
Gynecologic Oncology Qualifying Examination: Clinical Decisions Guide Study Guide
Practise staging, treatment selection, hereditary-risk interpretation, perioperative decisions and toxicity assessment across the nine ABOG gynecologic oncology competency domains.
By CertMedbry · Updated 15 October 2026
Build defensible decisions about disease extent, surgical candidacy, radiation, systemic treatment, inherited risk and urgent complications. Each concept connects a clinical principle with an application and a common error. This selective 60-concept guide supports preparation for the written Gynecologic Oncology Qualifying Examination. The official ABOG competency outline defines the full scope, including operative techniques, rare tumors, complex inpatient care and placenta accreta spectrum that require additional study.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification examination does this guide address?
The written Gynecologic Oncology Qualifying Examination within American Board of Obstetrics and Gynecology subspecialty certification. ABOG certification is voluntary physician board certification; medical licensure is a separate credential.
ABOG subspecialty-certification blueprint listing · ABOG Gynecologic Oncology competency blueprint
How does the Qualifying Examination differ from the Certifying Examination?
The Qualifying Examination is the written examination addressed here. The oral Certifying Examination is a separate certification step. These independently authored learning materials are not official ABOG examination items.
Where should examination duration, delivery and question-count information be checked?
Use the ABOG bulletin applicable to your examination administration for duration, delivery, question counts, scheduling and other operational requirements. The competency outline establishes content scope and does not establish those details.
ABOG subspecialty-certification blueprint listing · ABOG Gynecologic Oncology competency blueprint
Which blueprint and effective date apply?
Scope follows the official Gynecologic Oncology competency outline linked from ABOG's subspecialty blueprint listing. The document states no explicit effective or update date. Its 2026 hosting path does not independently establish an implementation date. Publication of the FIGO 2026 trophoblastic revision likewise does not establish an ABOG examination adoption date.
ABOG subspecialty-certification blueprint listing · ABOG Gynecologic Oncology competency blueprint
Does this guide cover the complete examination scope?
No. The official outline defines the full scope. This guide selects 60 concepts across all nine domains; additional study is needed for the outline's operative procedures, uncommon histologies, critical care, treatment-specific pharmacology and placenta accreta spectrum.
Are the domain allocations official examination weights?
No numeric domain weights are stated in the outline. The guide contains eight concepts each for ovarian, uterine and cervical cancer; four vaginal; six each vulvar and trophoblastic disease; seven complications; six post-treatment; and seven applied basic science. These counts are an educational selection.
How should the practice questions and clinical references be used?
The 20 four-option questions and 20 flashcards support learning rather than predict an examination result. NCI PDQ summaries review clinical evidence rather than state formal NCI treatment policies. The cited ESGO vulvar pocket guideline identifies itself as Update 2023 despite its 2026 hosting path.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) · ESGO Pocket Guidelines: Vulvar Cancer — Update 2023
Clinical decisions depend on integrating anatomy, pathology, molecular findings, treatment history and patient priorities. The concepts emphasize findings that change a classification or management branch and distinguish those findings from supportive but insufficient evidence.
Outline used: Workbook label mapped to ABOG's written Gynecologic Oncology Qualifying Examination within subspecialty certification; the assigned slug is preserved. Scope uses the currently linked competency blueprint documented in the supplied frozen issuer retrieval of 2026-10-08. Its URL contains a 2026 resource path, but the document has no stated effective/update date or numeric topic weights. Fresh issuer opening attempts on 2026-10-09 failed; live searches identified no newer qualifying-examination blueprint. The oral Certifying Examination is a separate certification step.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Ovarian/fallopian/peritoneal cancernot stated
1.Why can high-grade serous cancer originate in the fallopian tube?
Many high-grade serous carcinomas arise from precursor lesions in the tubal fimbria. Access to the peritoneal cavity helps explain early dissemination despite a small primary lesion. Epithelial ovarian, fallopian tube and primary peritoneal cancers share staging and treatment principles. Endometrioid, clear cell and low-grade serous tumors nevertheless have distinct biological features.
Apply it
A risk-reducing specimen contains serous tubal intraepithelial carcinoma despite grossly normal ovaries. Explain why thorough tubal examination matters and why salpingo-oophorectomy does not eliminate every subsequent primary peritoneal cancer risk.
Common pitfall: Normal ovarian appearance does not exclude a relevant tubal precursor. Applying high-grade serous biology to every ovarian histology also obscures clinically important differences.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
2.How should CA-125 influence evaluation of an adnexal mass?
CA-125 supports clinical evaluation but does not establish a tissue diagnosis. It may increase with epithelial ovarian cancer, other malignancies and benign conditions such as endometriosis. A low result does not exclude malignancy, especially when a tumor produces little marker. Symptoms, examination, imaging morphology and histology determine the significance of the result.
Apply it
A premenopausal patient has pelvic pain, an endometrioma-like mass and elevated CA-125. Integrate structural findings and clinical context before estimating malignancy risk; the marker cannot independently distinguish endometriosis from cancer.
Common pitfall: A high value can encourage premature cancer labeling, while a normal value can falsely reassure against a suspicious mass. Neither result replaces evaluation of the lesion.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
3.Which findings distinguish ovarian stage IC substages?
For disease otherwise confined to an ovary or fallopian tube, IC1 denotes surgical spill. IC2 denotes rupture before surgery or tumor on the ovarian or tubal surface. IC3 denotes malignant cells in ascites or peritoneal washings. Recording rupture timing, surface involvement and cytology separately preserves the distinctions underlying these categories.
Apply it
An initially intact ovarian tumor ruptures during removal. Its surface is uninvolved, washings are negative and staging reveals no extraovarian disease. The documented operative spill supports IC1.
Common pitfall: Grouping all rupture together loses the distinction between surgical and preoperative rupture. Positive washings also differ from visible peritoneal implants, which require assessment under the broader staging system.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
4.How do peritoneal implants differ from distant ovarian metastases?
Macroscopic extrapelvic peritoneal metastases exceeding 2 cm support stage IIIC, including liver or splenic capsular involvement without parenchymal invasion. Parenchymal metastases support IVB. Pleural effusion establishes IVA only when cytology is positive. Anatomical compartment and confirmation therefore matter more than proximity to a particular organ or the mere presence of thoracic fluid.
Apply it
A 3-cm liver capsular deposit is confirmed without parenchymal involvement. Pleural fluid cytology is negative and no other distant disease is found. The established findings support IIIC.
Common pitfall: Calling every liver-associated deposit distant disease confuses surface implantation with parenchymal metastasis. An effusion alone likewise does not satisfy the positive-cytology requirement for IVA.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
5.Why does apparent early ovarian cancer require comprehensive staging?
A tumor appearing confined to an ovary can have occult peritoneal or nodal spread. Staging integrates washings, systematic inspection, peritoneal sampling, omental assessment and appropriate nodal evaluation. These findings establish extent and influence interpretation of adjuvant-treatment evidence. Removal of the visible mass alone provides less confidence that a favorable early-stage presentation has been established.
Apply it
A patient is referred after ovarian carcinoma removal without washings, omental sampling or documented peritoneal assessment. Explain that histology is established, but uncertainty about extent remains relevant to further management.
Common pitfall: Small tumor size and negative imaging do not establish complete surgical staging. Observation results from carefully selected, adequately staged patients cannot automatically be transferred to an incompletely assessed patient.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
6.When is neoadjuvant therapy reasonable in advanced ovarian cancer?
Advanced epithelial ovarian cancer treatment integrates platinum-based chemotherapy with surgery when feasible. Primary cytoreduction is favored when complete gross resection appears achievable with acceptable morbidity. Neoadjuvant chemotherapy followed by interval reassessment is an established alternative when disease distribution or physiological condition makes an effective initial operation unlikely or excessively hazardous.
Apply it
Biopsy confirms high-grade serous carcinoma in a debilitated patient with extensive upper abdominal disease. Compare realistic complete-resection prospects with chemotherapy first, followed by reassessment of operability after response and functional improvement.
Common pitfall: Removing some tumor is not equivalent to achieving the intended cytoreductive endpoint. Choosing chemotherapy first also does not remove the obligation to reassess suitability for interval surgery.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
7.Why does low-grade serous carcinoma require a distinct treatment model?
Low-grade serous carcinoma is relatively resistant to cytotoxic chemotherapy and differs biologically from high-grade serous carcinoma. Hormone-receptor expression and MAPK-pathway biology support endocrine and selected targeted approaches in recurrent disease. Trametinib improved progression-free survival against physician-selected treatment; benefit was not restricted to identified BRAF, KRAS or NRAS variants. Binimetinib did not reproduce that randomized result.
Apply it
For slowly progressive, receptor-positive recurrence after platinum treatment, compare endocrine therapy, trametinib and surgical suitability. Absence of an identified MAPK-pathway variant does not alone exclude potential trametinib benefit.
Common pitfall: A pathway alteration does not guarantee response. Evidence for one MEK inhibitor cannot automatically establish efficacy or identical eligibility for another agent or combination.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
8.How do genetic results inform ovarian maintenance treatment and hereditary counseling?
For advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy, a qualifying pathogenic germline or somatic BRCA1/BRCA2 alteration can support olaparib maintenance eligibility. Germline confirmation is not required for a pathogenic somatic alteration to have therapeutic relevance. Tumor testing alone, however, cannot establish inherited risk. Germline assessment separately determines whether the alteration is constitutional and informs counseling of relatives.
Apply it
A patient with stage III high-grade serous ovarian carcinoma achieves a complete response to first-line carboplatin and paclitaxel. Tumor testing identifies a qualifying pathogenic BRCA1 alteration. Olaparib maintenance is an appropriate treatment option, while germline testing addresses hereditary risk. A negative germline result does not erase the treatment relevance of the somatic finding.
Common pitfall: A BRCA variant of uncertain significance does not establish BRCA-based maintenance eligibility or justify predictive testing of relatives as though it were pathogenic. Progression during platinum chemotherapy does not satisfy the response requirement for this first-line maintenance example. First-line maintenance and maintenance after treatment of recurrent disease are separate clinical indications; eligibility in one setting should not be assumed to establish eligibility in the other.
BRCA Gene Changes: Cancer Risk and Genetic Testing · Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) · Olaparib - NCI
Uterine cancernot stated
9.How should response to conservative EIN treatment be assessed?
Hysterectomy is definitive treatment for endometrial intraepithelial neoplasia or atypical endometrial hyperplasia. Before conservative management, attempt to exclude concurrent carcinoma. Patients avoiding surgery require progestin treatment and repeat histological assessment within 3–6 months after treatment begins. If there is no response after 9–12 total months, discuss other management options, including definitive surgery. Residual EIN represents persistence; carcinoma represents progression and requires reassessment within a cancer-treatment framework.
Apply it
Bleeding improves, but sampling at three months still shows EIN. Review treatment adequacy and continued conservative-management suitability, with further tissue assessment. Continued nonresponse after 9–12 total months warrants discussion of alternative management, including hysterectomy. A biopsy showing carcinoma requires a cancer assessment rather than waiting for that nonresponse interval.
Common pitfall: Improved bleeding or ultrasound appearance does not establish histological regression. Persistent EIN and progression to carcinoma are different findings; neither supports indefinite progestin treatment without scheduled tissue reassessment.
10.Which endometrial cancers may permit fertility preservation?
Conservative treatment may be considered for carefully selected patients with grade 1 endometrioid carcinoma confined to the endometrium. Expert pathological assessment and evaluation for myometrial or extrauterine disease are essential. Progestin treatment requires repeated endometrial assessment because clinical improvement does not establish complete response and recurrence remains possible after apparent regression.
Apply it
A young patient requests uterine preservation after a grade 1 diagnosis. Establish invasion and disease extent, review pathology and discuss the surveillance commitment before deciding whether conservative treatment is appropriate.
Common pitfall: Young age alone does not establish eligibility. Deep invasion, extrauterine disease or an unsuitable histology changes the treatment problem, and preservation of the uterus does not guarantee pregnancy or eliminate later definitive-treatment needs.
11.How do pathological and molecular risk factors determine endometrial adjuvant treatment?
Adjuvant treatment should address the expected location and probability of recurrence. Integrate histology, grade, depth of myometrial invasion, lymphovascular space invasion (LVSI), cervical involvement, margins, nodes and molecular classification. Observation is appropriate for selected completely resected low-risk cancers. Vaginal brachytherapy concentrates radiation at the vaginal cuff to reduce vaginal recurrence. Pelvic external-beam radiation treats a broader region, including pelvic nodal basins, when pelvic recurrence risk warrants it. Chemotherapy addresses systemic relapse risk in high-risk or extrauterine disease; radiation does not replace that systemic role.
Apply it
After hysterectomy, a grade 1 endometrioid carcinoma with 20% myometrial invasion, absent LVSI, negative assessed nodes and clear margins supports observation when it is estrogen-receptor positive, mismatch-repair proficient, p53 wild type and lacks a pathogenic POLE mutation, placing it in the no-specific-molecular-profile group. For a 68-year-old with otherwise similar findings but 60% invasion, vaginal brachytherapy is a reasonable adjuvant choice to reduce cuff recurrence without routinely irradiating pelvic nodes. In contrast, completely resected serous carcinoma with 70% invasion, substantial LVSI, a positive pelvic node, negative para-aortic nodes and clear margins warrants systemic chemotherapy, commonly carboplatin plus paclitaxel, with pelvic external-beam radiation addressing pelvic control. Specify p53-abnormal, mismatch-repair-proficient, POLE-wild-type classification in this high-risk example.
Common pitfall: A negative margin does not eliminate occult systemic disease, and negative nodes do not erase adverse uterine biology. Conversely, superficial low-grade disease does not automatically require radiation. Vaginal brachytherapy and pelvic external-beam treatment have different target volumes and toxicity burdens; select the field according to recurrence risk rather than treating all radiation as interchangeable.
12.How does molecular classification change prognosis and adjuvant-treatment reasoning in endometrial cancer?
The four principal molecular categories are pathogenic POLE exonuclease-domain–mutated, mismatch-repair deficient, p53 abnormal and no specific molecular profile. Qualifying pathogenic POLE alterations confer a particularly favorable prognosis, even when morphology appears high grade. Conversely, p53-abnormal disease generally carries an adverse prognosis. Molecular classification therefore refines recurrence-risk assessment beyond histological grade alone. Interpretation remains dependent on anatomical extent, completeness of resection and other pathological findings. Mismatch-repair deficiency also informs hereditary evaluation and eligibility for relevant immunotherapy regimens; it does not by itself establish Lynch syndrome.
Apply it
After complete resection, a patient has uterine-confined grade 3 endometrioid carcinoma, negative nodes and no substantial lymphovascular invasion. Sequencing confirms a recognized pathogenic POLE exonuclease-domain alteration. This changes counseling from concern based on high-grade morphology alone to recognition of favorable molecular prognosis and supports discussing observation and omission of adjuvant treatment in this early-stage setting. A comparable POLE-wild-type, p53-abnormal invasive tumor instead warrants discussion of higher recurrence risk and appropriate adjuvant treatment.
Common pitfall: A POLE variant of uncertain significance does not establish the favorable POLE-mutated category. Confirm pathogenicity before changing risk assessment. Favorable early-stage outcomes must not be extrapolated automatically to unresected or advanced disease, and abnormal p53 staining must be interpreted within the complete molecular classification.
13.How does MLH1 methylation clarify an abnormal mismatch-repair screen?
Loss of MLH1 commonly produces paired PMS2 loss because the proteins function together. Endometrial MLH1 promoter methylation can explain this pattern through acquired gene silencing, making a sporadic mechanism more likely. An unmethylated result strengthens the indication for hereditary evaluation. Tumor protein loss is a screening finding rather than proof of germline Lynch syndrome.
Apply it
An endometrial tumor lacks MLH1 and PMS2 but retains MSH2 and MSH6. Assess MLH1 promoter methylation before interpreting the finding as evidence of inherited MLH1 dysfunction.
Common pitfall: BRAF testing used in colorectal algorithms does not replace endometrial MLH1 methylation assessment. Neither immunohistochemistry nor a tumor-only result should be described to relatives as a confirmed inherited diagnosis.
14.Why is uterine carcinosarcoma managed as a high-risk carcinoma?
Carcinosarcoma contains malignant epithelial and mesenchymal-appearing components but is understood as a metaplastic carcinoma. Its aggressive behavior warrants high-risk endometrial cancer reasoning rather than the framework for an ordinary low-grade endometrioid tumor or pure uterine sarcoma. Surgical assessment of extent and consideration of systemic treatment reflect that biological interpretation.
Apply it
A specimen contains malignant glands and malignant spindle cells. Explain why their coexistence supports carcinosarcoma and a high-risk carcinoma treatment discussion rather than classification solely by the spindle-cell component.
Common pitfall: The historical name malignant mixed Müllerian tumor can encourage misleading categorization. Biphasic morphology does not necessarily indicate two independent primary cancers, and the sarcomatous appearance should not override the integrated diagnosis.
15.When is endocrine treatment useful for recurrent endometrial cancer?
Endocrine treatment is particularly attractive for well-differentiated, hormone-receptor-positive recurrence with an indolent clinical course. These findings support retained hormonal dependence and permit consideration of a less intensive systemic approach. Rapid progression, substantial symptoms or threatened organ function can favor treatment intended to produce faster control. Receptor status must therefore be integrated with disease tempo and burden.
Apply it
Small receptor-positive pulmonary metastases have enlarged slowly and cause minimal symptoms. Compare endocrine treatment with more intensive therapy, emphasizing the absence of immediate organ threat and the patient's priorities.
Common pitfall: Receptor positivity alone does not resolve a treatment decision when rapid control is needed. Conversely, recurrence does not automatically require immediate cytotoxic treatment when a suitable lower-intensity option exists.
16.When can isolated vaginal recurrence of endometrial cancer be salvaged?
An isolated vaginal recurrence after surgery may remain amenable to curative-intent radiation, especially when the pelvis has not previously been irradiated. Biopsy establishes recurrence, and regional and distant assessment determines whether it is isolated. External-beam radiation and brachytherapy can be combined according to extent and geometry. Previous radiation changes normal-tissue tolerance and available salvage options.
Apply it
A patient treated with hysterectomy alone develops a biopsy-confirmed cuff recurrence without detected nodal or distant spread. Discuss definitive radiation-based salvage rather than assuming recurrence requires exclusively palliative systemic treatment.
Common pitfall: Recurrence is not synonymous with incurability. However, a similar-looking lesion in a previously irradiated pelvis cannot automatically receive the same radiation plan without evaluating prior exposure and tissue tolerance.
Cervical cancernot stated
17.Why does persistent high-risk HPV drive cervical carcinogenesis?
Persistent high-risk HPV infection can sustain expression of the viral oncogenes E6 and E7. E6 promotes degradation of p53, impairing DNA-damage responses and the elimination of damaged cells. E7 binds and disrupts retinoblastoma-protein-mediated cell-cycle restraint, releasing E2F-driven proliferation. Sustained expression therefore permits inappropriate proliferation despite accumulated damage and supports progression to precancer and cancer. Most infections resolve; persistence is a risk state rather than a diagnosis of invasive cancer.
Apply it
A vaccinated patient has persistent high-risk HPV and high-grade cytology. Explain how sustained E6 and E7 activity undermines damage control and cell-cycle restraint, why diagnostic tissue evaluation remains necessary, and why vaccination does not treat an established lesion.
Common pitfall: HPV positivity alone does not establish stromal invasion. Vaccination prevents new infections with covered types but does not eradicate established cancer or replace evaluation of high-grade abnormalities.
18.How does conization clarify suspected microinvasive cervical cancer?
An appropriately obtained excisional specimen can establish stromal invasion and permit assessment of invasion depth, margins and lymphovascular space invasion. These findings distinguish preinvasive disease from selected microinvasive cancers and influence conservative-treatment suitability. A superficial or fragmented biopsy may establish abnormal cells without preserving enough architecture for reliable measurement or margin interpretation.
Apply it
A punch biopsy suggests early invasion but cannot establish its depth. Obtain an interpretable excisional specimen before choosing definitive treatment from the limited initial sample.
Common pitfall: Ablation before invasion is adequately excluded destroys tissue needed for classification. Positive or uninterpretable margins also limit confidence that the invasive focus has been fully characterized and appropriately removed.
19.Which nodal findings establish cervical stage IIIC?
Cervical stage IIIC1 denotes pelvic nodal involvement, whereas IIIC2 denotes para-aortic nodal involvement. The suffix r identifies imaging-based assignment and p identifies pathological confirmation. Local tumor extent should still be documented because patients sharing a nodal category can have very different primary disease burdens. The suffix also preserves the distinction between suspected and pathologically demonstrated nodal metastasis.
Apply it
A locally cervical-confined tumor has a biopsy-proven pelvic nodal metastasis without para-aortic disease. Assign IIIC1p while separately recording primary size and local extent for planning.
Common pitfall: Pelvic regional nodes do not constitute distant metastatic disease. Omitting the primary tumor description after assigning IIIC also discards information needed to interpret prognosis and plan treatment.
20.Why does surgical approach matter for radical hysterectomy?
When radical hysterectomy is selected for early cervical cancer, comparative oncological outcomes inform the operative approach. Randomized evidence found worse disease-free and overall survival with minimally invasive radical hysterectomy than with an open abdominal approach in the studied population. Smaller incisions and recovery advantages cannot independently establish equivalent cancer control for this procedure.
Apply it
A patient requests robotic radical hysterectomy because of expected recovery benefits. Explain the comparative survival findings and distinguish this operation from minimally invasive procedures used for other gynecologic cancers.
Common pitfall: Technical feasibility does not establish oncological equivalence. The converse claim that all minimally invasive gynecologic cancer surgery is inferior also exceeds evidence concerning this specific operation and disease setting.
21.Which explicit criteria determine suitability for cervical fertility-preserving surgery?
Conization alone may adequately treat selected stage IA1 cervical cancers with invasion no greater than 3 mm, absent lymphovascular space invasion and negative margins. For radical trachelectomy, the NCI framework describes typical candidates as having presumed stage IA2–IB1 disease, a lesion no greater than 2 cm and sufficient upper cervical clearance to achieve negative margins while preserving the uterine corpus. Suitable histology includes squamous carcinoma and usual-type adenocarcinoma. Required regional nodal assessment must be negative; negative imaging alone does not establish pathological nodal negativity. Aggressive histologies, including neuroendocrine carcinoma, are unsuitable for this standard preservation pathway.
Apply it
A completely excised IA1 squamous carcinoma with 2 mm stromal invasion, no lymphovascular invasion and negative margins can support conization-based preservation. A 1.5 cm squamous carcinoma with 6 mm invasion, no parametrial or upper cervical extension, negative surgical pelvic nodal assessment and achievable negative resection margins is a potential trachelectomy candidate under the stated framework. A 2.5 cm lesion exceeds its 2 cm size criterion even if imaging shows no enlarged nodes; reproductive preference does not make that lesion eligible under these criteria.
Common pitfall: Measure the tumor rather than describing it merely as small. Tumor diameter, upper endocervical extent, histology, nodes and margins answer different eligibility questions. Positive nodes or an unachievable negative upper margin can require abandoning the planned preservation approach. Preserving the uterus also does not guarantee conception or an uncomplicated pregnancy.
22.Why combine chemotherapy and radiation for locally advanced cervical cancer?
Concurrent chemotherapy acts as a radiosensitizer while radiation provides definitive local and regional treatment. Cisplatin-based concurrent treatment improves outcomes compared with radiation alone in appropriate locally advanced disease. External-beam radiation addresses pelvic and relevant nodal regions, while brachytherapy provides concentrated central treatment. Treatment tolerance and renal function influence delivery, but chemotherapy alone does not reproduce the complete regimen's local curative role.
Apply it
A bulky cervical tumor extends into the parametria without distant metastases. Plan definitive chemoradiation including brachytherapy rather than assuming hysterectomy or systemic chemotherapy alone supplies equivalent treatment.
Common pitfall: Completing external-beam radiation does not make brachytherapy dispensable. Describing the chemotherapy component as a substitute for definitive local treatment also misunderstands the complementary roles of the regimen.
23.How does cervical tumor geometry guide brachytherapy placement?
Brachytherapy places radiation sources within or close to the target, delivering a high local dose with rapid reduction over distance. Intracavitary applicators suit some central targets; interstitial needles can improve coverage of asymmetric, bulky or lateral residual disease. Source geometry must balance target coverage with bladder, rectal and other normal-tissue exposure.
Apply it
A standard intracavitary plan undercovers lateral residual tumor unless rectal exposure becomes excessive. Consider combined intracavitary-interstitial placement to change source position rather than simply increasing treatment time in the same geometry.
Common pitfall: Using identical applicators for every tumor can underdose the target or overdose adjacent organs. An external-beam boost is not automatically an equivalent substitute for appropriately placed brachytherapy.
Cervical Cancer Treatment (PDQ) · Brachytherapy to Treat Cancer
24.When can pelvic exenteration address recurrent cervical cancer?
Exenteration may offer curative potential for highly selected central pelvic recurrences, particularly after prior radiation, when complete resection appears feasible and distant disease is absent. Selection requires defining extent, estimating margin prospects and assessing physiological and psychosocial capacity for major surgery and reconstruction. Central location is therefore an initial clue rather than sufficient eligibility.
Apply it
A previously irradiated patient has a biopsy-confirmed central recurrence without detected metastases. Assess realistic negative-margin resection and discuss urinary, bowel and sexual consequences before presenting exenteration as an option.
Common pitfall: Pelvic recurrence alone does not establish resectability. Conversely, prior radiation does not prove every recurrence is unsalvageable; carefully selected patients may retain a meaningful local treatment opportunity.
Vaginal cancernot stated
25.How is primary vaginal cancer distinguished from adjacent-site extension?
A vaginal lesion can represent a vaginal primary, extension from the cervix or vulva, or recurrence from another cancer. Classification integrates adjacent-site examination, previous cancer history, imaging and pathology. Cervical cancer extending into the vagina remains classified within the cervical framework. The most visible or readily biopsied component does not necessarily identify the primary site.
Apply it
A vaginal mass is continuous with a cervical tumor, and imaging places its center in the cervix. Use the cervical staging framework rather than classifying it from the vaginal biopsy location alone.
Common pitfall: Biopsy establishes histology but may not establish origin. Ignoring an adjacent lesion or previous malignancy can select the wrong staging system and distort regional treatment planning.
26.How does local extension distinguish vaginal cancer stages?
Stage I vaginal cancer is confined to the vaginal wall. Stage II involves subvaginal tissue without reaching the pelvic wall, and stage III reaches the pelvic wall. Stage IVA includes bladder or rectal mucosal invasion or extension beyond the true pelvis; IVB denotes distant spread. Anatomical boundaries crossed determine these distinctions rather than tumor bulk alone.
Apply it
A vaginal tumor extends into surrounding tissue without pelvic-wall involvement or bladder or rectal mucosal invasion. The documented local findings support stage II.
Common pitfall: Contact with the bladder or rectum does not independently prove mucosal invasion. Symptoms or edema can raise concern, but they should not be substituted for the anatomical evidence required by a staging definition.
27.Why does vaginal tumor location affect regional treatment?
Vaginal lymphatic drainage varies along its length. Upper vaginal tumors principally involve pelvic nodal pathways, whereas lower vaginal disease can drain to inguinal nodes. Tumors spanning regions require assessment of the relevant combined drainage pathways. This anatomy influences both nodal evaluation and radiation planning, in addition to treatment of the primary tumor.
Apply it
A squamous carcinoma involves the lower third of the vagina. Include the groins in regional assessment and field planning rather than assuming every vaginal lesion drains exclusively to pelvic nodes.
Common pitfall: The biopsy location may not represent the tumor's full longitudinal extent. Applying upper-vaginal drainage assumptions to a distal or extensive lesion can leave an important regional pathway inadequately assessed.
28.When must a suspicious vaginal lesion be sampled before ablation?
Before treating presumed vaginal intraepithelial disease, adequate tissue assessment must address possible invasion. Thickening, ulceration or incomplete visualization increases concern that superficial sampling may be insufficient. An excisional approach can provide architecture when the invasion question remains unresolved. Ablation destroys tissue and therefore cannot supply the specimen needed to answer that question afterward.
Apply it
High-grade cytology accompanies a thickened lesion partly hidden in a cuff scar. Assess the concealed component and obtain adequate tissue before selecting an ablative treatment.
Common pitfall: A negative biopsy from a separate visible area does not characterize an inaccessible suspicious focus. Treating every high-grade lesion as safely ablatable can erase evidence needed to recognize invasive cancer.
Vulvar cancernot stated
29.Why does a suspicious vulvar lesion require tissue diagnosis?
Vulvar plaques, ulcers and pruritus have inflammatory, preinvasive and invasive causes that cannot reliably be distinguished by appearance alone. Biopsy establishes histology and can assess invasion when appropriately obtained. Suspected invasion changes management because topical treatment or ablation cannot provide complete invasive pathology or address nodal risk. Heterogeneous lesions may require more than one representative sample.
Apply it
A persistent ulcer develops within a plaque repeatedly treated as dermatitis. Sample the suspicious focus before another empirical topical course and use the pathological findings to determine the treatment pathway.
Common pitfall: Improvement in itching does not exclude cancer. Sampling only the least abnormal edge can also miss an invasive component within a broader lesion and create false reassurance.
30.How does vulvar Paget disease differ from squamous neoplasia?
Extramammary Paget disease is a glandular intraepithelial neoplasm that can resemble chronic eczema. Histology and appropriate special studies distinguish it from dermatitis, squamous lesions and melanoma. Microscopic spread may exceed visible borders, contributing to local recurrence. Assessment also needs to establish whether invasion or an associated underlying malignancy changes the treatment problem.
Apply it
A persistent pruritic plaque fails dermatitis treatment and biopsy identifies Paget cells. Assess extent and invasion rather than applying an interchangeable squamous intraepithelial disease pathway.
Common pitfall: An eczema-like appearance can delay diagnosis. Assuming the visible margin contains all disease also overlooks subclinical extension, while assuming every Paget lesion is purely intraepithelial can miss a clinically important invasive component.
31.Which vulvar squamous carcinomas require groin assessment and qualify for sentinel-node assessment?
Vulvar squamous carcinomas with stromal invasion greater than 1 mm require groin staging. Sentinel-node assessment is recommended for unifocal tumors smaller than 4 cm with invasion greater than 1 mm and clinically and radiologically nonsuspicious inguinofemoral nodes. Multifocal invasive disease, tumors measuring at least 4 cm, and suspicious nodes fall outside this standard sentinel pathway. T1a disease requires confinement to the vulva or perineum, diameter no greater than 2 cm, and invasion no greater than 1 mm; these tumors ordinarily require no groin treatment. For treatment planning, ESGO 2023 advises conventional invasion measurement: from the epithelial–stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion.
Apply it
A unifocal 2.5-cm vulvar squamous carcinoma with 3-mm conventional stromal invasion and nonsuspicious groins meets standard sentinel-node eligibility criteria. Both its diameter and invasion exceed T1a limits, and its invasion clearly establishes the indication for groin staging. In contrast, a 1.8-cm carcinoma with 0.8-mm conventional invasion confined to the vulva meets both T1a limits and ordinarily requires no groin treatment. Record tumor diameter, focality, invasion measurement method, and groin findings separately.
Common pitfall: A 2.5-cm tumor with 0.8-mm invasion illustrates conflicting wording within ESGO 2023: its formal recommendations call for groin treatment above T1a, which includes this tumor because of size, whereas its narrative exempts tumors with invasion no greater than 1 mm. Therefore, the above-T1a approach must be attributed to those formal recommendations; mandatory groin surgery for every larger, shallowly invasive tumor is not an unqualified consensus rule. Also distinguish conventional invasion depth from the FIGO 2021 method using the deepest adjacent dysplastic, tumor-free rete ridge, because the measurements can differ.
Vulvar Cancer Treatment (PDQ) · ESGO Pocket Guidelines: Vulvar Cancer — Update 2023 · European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023 - PMC
32.Why do non-lateralized vulvar tumors require bilateral groin assessment?
Vulvar lymphatic drainage can cross the midline. ESGO defines a non-lateralized tumor by a medial border less than 1 cm from the midline; these tumors require bilateral groin assessment. For an eligible sentinel procedure, bilateral detection is necessary. If a sentinel node is not detected in a required groin, inguinofemoral lymphadenectomy is indicated in that groin.
Apply it
An otherwise eligible unifocal carcinoma has its medial border 0.5 cm from the midline. Plan bilateral sentinel mapping. If only the left side maps, a negative left sentinel node does not complete assessment: the unmapped right groin requires inguinofemoral lymphadenectomy.
Common pitfall: Measure from the medial tumor border rather than the tumor center or larger visible portion. A lesion need not cross the midline to require bilateral assessment, and failed mapping must not be interpreted as a negative node.
33.How does the size of a positive vulvar sentinel-node deposit determine subsequent groin treatment?
Under ESGO 2023 guidance, a positive sentinel node requires additional treatment of the involved groin. Isolated tumor cells or sentinel-node metastases no greater than 2 mm can be treated with inguinofemoral radiotherapy instead of completion inguinofemoral lymphadenectomy. A metastasis greater than 2 mm requires inguinofemoral lymphadenectomy on the affected side. Radiotherapy alone did not provide adequate groin control in this macrometastatic group. Subsequent adjuvant radiotherapy decisions incorporate the completed nodal findings, including additional involved nodes and extranodal extension.
Apply it
A newly diagnosed, unifocal 2.5-cm vulvar squamous carcinoma with 3-mm stromal invasion and clinically and radiologically nonsuspicious groins meets standard sentinel-node selection criteria. For ESGO treatment planning, use the conventional TNM eighth-edition invasion measurement: from the epithelial–stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. If sentinel-node ultrastaging identifies a 1.5-mm right-sided deposit, right groin radiotherapy is an alternative to completion dissection. A 3-mm deposit instead warrants right inguinofemoral lymphadenectomy. Confirm adequate assessment of every groin requiring staging.
Common pitfall: Anatomical T1a classification requires both tumor diameter no greater than 2 cm and stromal invasion no greater than 1 mm. Treatment-selection statements differ: ESGO's full 2023 guideline text exempts tumors with invasion no greater than 1 mm, whereas its pocket recommendations use disease above T1a, and BC Cancer uses diameter greater than 2 cm or invasion greater than 1 mm. These formulations conflict for a 2.5-cm tumor with 0.8-mm invasion; do not teach mandatory groin surgery as a universal rule for that presentation. Do not substitute the FIGO 2021 alternative invasion measurement when applying ESGO's conventional treatment thresholds. For positive sentinel nodes, exactly 2 mm remains eligible for radiotherapy instead of completion dissection; isolated tumor cells are not a negative result.
ESGO Pocket Guidelines: Vulvar Cancer — Update 2023 · European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023 - PMC · 5.3 Management
34.When can chemoradiation reduce the burden of vulvar surgery?
Locally advanced vulvar cancer may involve structures whose removal would impose major urinary or bowel morbidity. Chemoradiation can provide definitive treatment or precede selected surgery. Treatment selection integrates local extent, nodal disease, resectability, functional consequences and tolerance. Response assessment remains essential because organ preservation is an objective rather than a guaranteed outcome.
Apply it
A carcinoma approaches the anus and urethra, making immediate surgery potentially exenterative. Compare chemoradiation with radical surgery in a multidisciplinary discussion that explicitly addresses tumor control and function.
Common pitfall: Technical resectability alone does not identify the best initial strategy. Conversely, promising organ preservation before response is established understates the possibility of residual disease and subsequent surgery.
Vulvar Cancer Treatment (PDQ) · ESGO Pocket Guidelines: Vulvar Cancer — Update 2023
Gestational trophoblastic diseasenot stated
35.How do morphology, p57 staining and genotyping distinguish complete from partial hydatidiform mole?
Typical sporadic complete moles have an entirely paternal diploid genome, diffuse hydropic villi and prominent circumferential trophoblastic proliferation. Partial moles usually have a diandric triploid genome, with two paternal chromosome complements and one maternal complement; mixed normal and abnormal villi, scalloped contours and fetal tissue may occur. Because p57 is maternally expressed and paternally imprinted, typical complete moles lack nuclear staining in villous stromal cells and cytotrophoblasts. Partial moles retain staining.
Apply it
Hydropic villi with absent p57 in both diagnostic cell populations and appropriately positive internal controls support complete mole. If p57 is retained but morphology suggests partial mole, genotyping can distinguish a diandric triploid conception from a nonmolar conception. Demonstrating two paternal complements and one maternal complement supports partial mole. This distinction matters because persistent trophoblastic disease occurs more often after complete than partial mole.
Common pitfall: Retained p57 establishes neither triploidy nor partial mole: nonmolar conceptions also commonly retain expression. Absent staining without valid internal controls is uninterpretable. Fetal tissue can accompany partial mole, and a coexisting twin pregnancy can complicate the usual absence of fetal tissue in complete mole. Rare familial complete moles may be biparental, so discordant morphology and ancillary results require integrated interpretation.
Placenta - CAP · Gestational Trophoblastic Disease Treatment (PDQ)
36.How do serial hCG patterns identify postmolar neoplasia?
After molar evacuation, quantitative hCG should decline as trophoblastic activity resolves. A plateau is less than 10% change across four measurements over at least three weeks. A diagnostic rise is greater than 10% across three consecutive weekly measurements over at least two weeks. These magnitude and timing criteria distinguish sustained abnormal trends from trivial fluctuation. Histological choriocarcinoma can establish disease independently. See FIGO 2026: https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.71229.
Apply it
Values of 1,000, 1,020, 990 and 1,010 IU/L on days 1, 7, 14 and 21 show less than 10% change over three weeks and support a plateau. Three consecutive weekly values showing a sustained rise greater than 10% meet the separate rising-pattern criterion.
Common pitfall: Two minimally different results do not establish either complete pattern. A rise of only a few percent is insufficient. Consider a new pregnancy or assay interference when low-level results conflict with the clinical setting.
37.How does FIGO 2026 GTN staging qualify pulmonary and nodal findings?
The historical framework summarized by NCI describes stage I as disease confined to the uterine corpus, stage II as other genital involvement, stage III as pulmonary metastases and stage IV as other metastatic sites. FIGO 2026 explicitly includes cervical involvement in stage I, assigns involved nodes below the diaphragm to stage III and involved nodes above the diaphragm to stage IV, and excludes pulmonary micrometastases from anatomical staging and prognostic scoring: qualifying lung lesions measure at least 1 cm. For imaging-defined likely involved lymph nodes, the short-axis threshold is at least 10 mm. Record imaging-based nodal assignment with LN r and pathological confirmation with LN p. Primary publication: https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.71229.
Apply it
Uterine GTN with an established 1.4-cm pulmonary metastasis and no stage IV disease is stage III. A likely involved infradiaphragmatic node measuring 12 mm in short axis, without pathological confirmation or stage IV disease, supports stage III LN r. Pathological confirmation changes the nodal notation to LN p. Isolated 4-mm pulmonary micrometastases do not establish stage III or increase the score under FIGO 2026.
Common pitfall: Location alone does not establish imaging-defined nodal involvement: apply the short-axis qualification and document the basis of assignment. Do not count every tiny pulmonary nodule as a staging or scoring metastasis. Anatomical stage remains separate from prognostic risk, and the historical NCI table does not supply the revised imaging instructions.
38.How does FIGO 2026 prognostic scoring differ from the historical modified WHO table?
The historical FIGO-associated modified WHO table summarized by NCI has eight factors: age, antecedent pregnancy, interval, pretreatment hCG, largest tumor size, metastatic site, number of metastases and previous failed chemotherapy. It groups scores 0–6 as low risk and at least 7 as high risk. FIGO 2026 removes previous chemotherapy from scoring and distinguishes high risk, scores 7–12, from ultra-high risk, scores at least 13. See https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.71229.
Apply it
A 28-year-old presents two months after a mole with hCG 20,000 IU/L, a 4-cm uterine tumor and no metastases or previous chemotherapy. hCG contributes two points and size one, totaling three: low risk. The absence of prior chemotherapy means removing that historical factor does not change this example.
Common pitfall: Identify the scoring version before calculating. Previous failed chemotherapy contributes to the historical table but is excluded from FIGO 2026 scoring; treatment history still matters clinically. Use hCG at GTN diagnosis before treatment, measure tumor rather than the whole uterus, and do not use this framework to direct placental-site trophoblastic tumor management.
39.Why does trophoblastic prognostic risk change treatment intensity?
Conventional low-risk GTN commonly receives single-agent methotrexate or dactinomycin, whereas high-risk disease generally requires multiagent chemotherapy. Prognostic scoring therefore guides intensity beyond anatomical stage alone. Serial hCG measures response and can reveal resistance even when symptoms are limited. Critical metastatic sites, bleeding and physiological instability also require coordinated urgent care rather than reliance on the numerical score alone.
Apply it
Two patients have lung metastases, but their prognostic scores are three and nine. Explain why both can have stage III disease while entering different initial chemotherapy-intensity pathways.
Common pitfall: Pulmonary metastases alone do not establish high-risk status. Conversely, a seemingly modest uterine presentation does not prove low risk when the full score contains adverse features.
40.How do stage and the interval from antecedent pregnancy to treatment initiation guide prognosis in PSTT and ETT?
Placental-site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT) are intermediate-trophoblast malignancies for which the conventional modified WHO numerical score is not applicable. Under FIGO 2026, stages I–III have a favorable prognostic designation (GP) when treatment begins less than 48 months after the antecedent pregnancy, and an unfavorable designation (PP) when treatment begins at or after 48 months. Document the anatomical stage and designation as stage:GP or stage:PP. Stage IV has poor prognosis regardless of this interval. PSTT may produce little hCG relative to tumor burden and is less chemotherapy-sensitive than typical gestational choriocarcinoma, making surgery central for uterine-confined disease. Primary publication, section 9: https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.71229.
Apply it
For stage I PSTT with treatment initiated 36 months after the antecedent pregnancy, document I:GP. If treatment begins at exactly 48 months, document I:PP. A patient with stage I ETT diagnosed 47 months after the antecedent pregnancy but beginning treatment at 49 months also has I:PP; the earlier diagnosis does not establish GP. Record the antecedent pregnancy date and treatment initiation date explicitly. Assess disease extent and surgical suitability rather than choosing single-agent chemotherapy from a modest hCG value.
Common pitfall: Do not measure the prognostic interval only to diagnosis: treatment initiation determines which side of the 48-month boundary applies. Exactly 48 months belongs to PP. Do not substitute the conventional GTN numerical score for the PSTT/ETT stage-and-interval designation. GP does not justify observation alone, and low hCG does not establish low tumor burden.
Complicationsnot stated
41.What immediate decisions are required for suspected febrile neutropenia?
Fever during chemotherapy requires urgent assessment because neutropenia impairs host defense. Febrile neutropenia warrants initial empirical antibacterial therapy within one hour of triage. Assess hemodynamic stability, obtain blood counts and cultures promptly, and avoid delaying treatment for laboratory confirmation of an organism. Unstable patients require inpatient management; outpatient treatment requires careful low-risk selection and reliable follow-up.
Apply it
A patient has temperature 38.4°C, ANC 200/µL and hypotension. Begin resuscitation and inpatient intravenous empirical treatment with antipseudomonal coverage while obtaining cultures without meaningful delay.
Common pitfall: Absence of a focal source does not reduce the urgency. Antipyretics can suppress temperature without treating infection, and a stable appearance alone does not establish outpatient eligibility.
Infection and Neutropenia and Cancer Treatment · ASCO/IDSA Clinical Practice Guideline Update for Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
42.How should suspected bowel obstruction be distinguished from uncomplicated constipation?
Distention, vomiting, cramping and reduced passage of gas or stool raise concern for obstruction rather than uncomplicated constipation. Prior abdominal surgery, radiation and ovarian cancer increase relevant risk. CT provides more precise information about site, cause and complications than plain radiographs. Initial supportive treatment includes bowel rest, volume resuscitation and correction of electrolyte abnormalities, with decompression and surgical assessment as indicated.
Apply it
A postoperative patient develops progressive distention, vomiting and absent flatus. Evaluate obstruction and its complications before escalating routine oral laxatives.
Common pitfall: Overflow diarrhea does not exclude obstruction or impaction. Persistent symptoms should not automatically be attributed to expected postoperative recovery, particularly when the pattern worsens or systemic illness develops.
43.How should neuropathy change functional and safety assessment?
Peripheral neuropathy can cause numbness, tingling, burning, weakness and impaired coordination. Mild pain does not imply mild functional injury. Loss of sensation or position awareness increases falls and burn risks, while hand symptoms can interfere with dressing and self-care. Assess progression and daily function before further neurotoxic treatment, while considering other neurological or metabolic causes.
Apply it
A patient receiving taxane treatment has little pain but stumbles and drops buttons. Assess balance, strength, sensation and treatment tolerance before the next dose, and give practical injury-prevention advice.
Common pitfall: Waiting until chemotherapy ends can allow additional exposure during worsening impairment. Conversely, automatically attributing every new neurological symptom to treatment can delay recognition of a different cause.
44.When should postoperative deterioration trigger assessment for an anastomotic leak?
After bowel resection, new or persistent tachycardia, worsening abdominal pain, fever, recurrent ileus, oliguria or enteric drain output should raise concern for an anastomotic leak and intra-abdominal infection. Assess perfusion and organ dysfunction while initiating resuscitation, broad-spectrum antibiotics and urgent surgical source-control assessment. In a sufficiently stable patient, contrast-enhanced CT can identify a collection or leak and guide drainage. Generalized peritonitis or hemodynamic instability requires urgent operative source-control assessment without delaying for imaging. These resuscitation and source-control branches follow [SIS/IDSA intra-abdominal infection guidance](https://academic.oup.com/cid/article/50/2/133/327316).
Apply it
On postoperative day five after rectosigmoid resection, a patient develops increasing pain, tachycardia, hypotension and feculent drain output. Begin sepsis resuscitation and urgent operative assessment for source control. A stable patient without generalized peritonitis who has a localized accessible collection may instead undergo image-guided drainage when that approach can adequately control contamination, with close reassessment for failure.
Common pitfall: Calling worsening ileus expected recovery can delay source control. Antibiotics alone do not reliably control ongoing enteric contamination, and a drainable collection does not justify delaying surgery for generalized peritonitis. Simultaneously assess other causes of postoperative shock: bloody drainage and falling hemoglobin suggest hemorrhage, requiring blood-product resuscitation and urgent bleeding control rather than antibiotics alone.
ABOG Gynecologic Oncology competency blueprint · Gastrointestinal Complications (PDQ®) - NCI
45.How should diarrhea during checkpoint treatment be graded and managed?
Use CTCAE v6.0 and assign the highest qualifying diarrhea grade. Grade 1 describes changed stool consistency or frequency without a higher criterion. Grade 2 includes four to six additional stools daily, a moderate increase in ostomy output or limitation of instrumental activities such as shopping or meal preparation. Grade 3 includes at least seven additional stools daily, hospitalization indicated, severely increased ostomy output, required intravenous intervention or limitation of self-care such as bathing or dressing. Grade 4 denotes life-threatening consequences requiring urgent intervention. Assess fecal incontinence separately; it alone does not establish grade 3 diarrhea. [Official CTCAE v6.0 criteria](https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v6.pdf).
Apply it
A patient whose baseline is one stool daily develops six stools daily without a higher criterion: five additional stools establish grade 2. Three additional stools with diarrhea-related inability to prepare meals also qualify as grade 2; self-care limitation or required intravenous intervention establishes grade 3 despite fewer than seven additional stools. Hold checkpoint treatment for grade 2 or worse, assess hydration and electrolytes, and obtain infectious stool studies including Clostridioides difficile testing. Suspected grade 2 immune-mediated disease generally requires prednisone approximately 1 mg/kg/day; severe disease generally requires 1–2 mg/kg/day prednisone-equivalent, with intravenous treatment and hospitalization as indicated.
Common pitfall: Diarrhea severity and clinically significant colitis require separate assessment. Blood, severe pain, distention or systemic illness can indicate serious colitis even with few stools and warrant urgent imaging, endoscopic assessment or inpatient care. Antidiarrheal improvement does not exclude inflammation. Persistent immune-mediated disease despite adequate corticosteroids for approximately 3–5 days warrants gastroenterology-directed escalation to infliximab or vedolizumab after assessing infection and contraindications. Once improved, taper steroids gradually, usually over at least 4–6 weeks. Treatment guidance: [SITC immune-related adverse-event guideline](https://jitc.bmj.com/content/9/6/e002435).
ctcae-v6.pdf · Immune Checkpoint Inhibitors · Gastrointestinal Complications (PDQ®) - NCI
46.How should suspected postoperative venous thromboembolism be evaluated?
New unilateral leg swelling or pain after cancer surgery warrants assessment for deep-vein thrombosis with compression ultrasonography. At intermediate or high clinical probability, a negative initial proximal study may require repeat proximal ultrasonography approximately one week later if no alternative diagnosis explains the symptoms. New dyspnea, pleuritic pain, tachycardia, hypoxemia or syncope raises concern for pulmonary embolism. In stable patients with likely pulmonary embolism, proceed to CT pulmonary angiography; ventilation-perfusion scanning is an alternative when CT is unsuitable, with further testing for nondiagnostic results. D-dimer is frequently positive after surgery and must not independently establish VTE. These probability-based pathways follow ASH diagnostic guidance.
Apply it
Pleuritic pain and hypoxemia a week after pelvic cancer surgery require investigation despite prophylaxis. Confirmed VTE requires therapeutic anticoagulation when bleeding risk permits. Initial cancer-associated VTE options include low-molecular-weight heparin or selected direct oral anticoagulants, with selection based on bleeding risk, renal function, drug interactions and reliable absorption. Active hemorrhage can preclude immediate anticoagulation. Clinical treatment reference: [ASH 2021 cancer-associated VTE guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC7903232/).
Common pitfall: Prophylactic dosing does not treat an established thrombus, and a normal leg examination does not exclude pulmonary embolism. Shock requires immediate cardiopulmonary support and urgent reperfusion assessment; routine thrombolysis is not recommended solely for right-ventricular dysfunction without hemodynamic compromise. Recent surgery heightens bleeding concerns when selecting reperfusion. See [ASH 2020 DVT and pulmonary embolism treatment guidance](https://pmc.ncbi.nlm.nih.gov/articles/PMC7556153/) and the [2026 acute pulmonary embolism guideline](https://www.jacc.org/doi/10.1016/j.jacc.2025.11.005) for hemodynamic and procedural treatment branches.
ABOG Gynecologic Oncology competency blueprint · American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism - PMC
47.How does the location of a recognized ureteral injury determine reconstruction?
Immediately recognized complete ureteral injury generally merits immediate repair when physiology and tissue permit. Use viable tissue, a watertight tension-free anastomosis and internal stenting. Distal injury usually favors ureteroneocystostomy because distal blood supply may be compromised. A psoas hitch reduces anastomotic tension. A short mid- or proximal defect may permit ureteroureterostomy. A Boari flap can bridge a longer mid-distal gap, but its complexity makes it unsuitable for the acute unstable setting. These operative branches follow EAU ureteral-injury guidance.
Apply it
During pelvic dissection in a stable patient, a distal ureter is transected and its short distal stump is devascularized. Debride nonviable tissue and reimplant the viable proximal ureter into the bladder, adding a psoas hitch if needed. If instability, infection or unsuitable tissue prevents definitive repair, establish urinary diversion, commonly nephrostomy, drain associated leakage and plan delayed reconstruction.
Common pitfall: Location, vascularity, bladder capacity and tissue condition matter alongside defect length. A stent cannot substitute for reconstruction of a complete transection, and thermal injury may declare itself later. Delayed diagnosis commonly warrants attempted stenting or nephrostomy first; persistent disruption requires reconstruction after stabilization.
ABOG Gynecologic Oncology competency blueprint · EAU Guidelines on Urological Trauma - UROGENITAL TRAUMA GUIDELINES
Post-treatment considerationsnot stated
48.Why does lymph-node treatment cause persistent limb swelling?
Lymph-node surgery and radiation can disrupt lymphatic transport, causing protein-rich fluid to accumulate in tissues. Lymphedema may present with heaviness, tightness and gradually developing swelling long after treatment. Its mechanism differs from thrombosis, infection or recurrent tumor obstruction, so a history of nodal treatment does not establish the cause of every swollen limb.
Apply it
A survivor develops gradual leg heaviness after pelvic nodal treatment. Assess lymphedema, while explaining why a later sudden painful or febrile change requires a new evaluation.
Common pitfall: Chronic lymphedema can coexist with an acute condition. Sudden onset, marked pain, redness or systemic symptoms should reopen the differential rather than reinforce an existing diagnosis without assessment.
49.How does decongestive treatment address cancer-related lymphedema?
Lymphedema management supports fluid movement and protects affected tissues. Individualized treatment can combine compression, exercise, manual lymphatic drainage and skin care through trained clinicians. The aim is sustained control of swelling, function and complications rather than a promise that damaged lymphatic pathways will normalize. Skin protection matters because infection can worsen lymphatic dysfunction.
Apply it
A patient requests a long-term plan for leg swelling. Arrange compression assessment and movement instruction, reinforce skin care and identify redness, warmth or fever as reasons for prompt reassessment.
Common pitfall: Poorly fitted compression may be ineffective or harmful. Treating limb volume while ignoring skin injury and infection risk also misses an important component of preventing deterioration.
50.When should palliative care begin during gynecologic cancer treatment?
Palliative care addresses physical symptoms, emotional distress, social concerns, spiritual needs and communication during serious illness. It can begin at diagnosis and continue alongside disease-directed treatment. Referral follows needs rather than a requirement to stop anticancer therapy. Concurrent oncology and palliative care can help patients tolerate treatment and make decisions consistent with their priorities.
Apply it
A patient starting advanced ovarian cancer treatment has pain, insomnia and family distress. Add palliative care now to address those needs while oncology treatment proceeds.
Common pitfall: Equating referral with imminent death delays support. A patient pursuing intensive therapy can still benefit from symptom management and communication assistance, and psychosocial concerns deserve attention alongside physical symptoms.
51.How does advance care planning support later treatment decisions?
Advance care planning explores values, acceptable treatment burdens and preferred decision-makers before a crisis limits participation. It is an ongoing discussion rather than a single form. Knowing whether communication, independence, longevity or another goal matters most helps interpret later choices. Documented priorities and an identified surrogate improve continuity when the patient becomes unable to speak.
Apply it
A patient wants further therapy but strongly values remaining able to communicate with family. Discuss acceptable tradeoffs, identify a surrogate and document the priorities that should guide future decisions.
Common pitfall: Reducing planning to resuscitation status overlooks broader goals. Preferences also require reconsideration when health, available options or the patient's understanding and priorities change.
52.How does hospice differ from concurrent palliative care?
Palliative care can accompany disease-directed treatment throughout serious illness. Hospice focuses on comfort and quality of life near the end of life when cure or disease control is no longer the treatment goal. Both involve active attention to symptoms and support needs. The distinction concerns the goals and organization of care rather than whether the patient deserves continued clinical attention.
Apply it
A patient decides further tumor-directed treatment would impose unacceptable burdens. Explain hospice support and continued treatment of pain, nausea, distress and caregiver needs.
Common pitfall: Describing hospice as abandonment misrepresents comfort-focused care. Requiring hospice enrollment before offering ordinary palliative support also confuses two care models and can unnecessarily delay useful help.
53.Why should isolated CA-125 elevation not automatically trigger treatment?
CA-125 can detect biochemical change before symptoms or imaging establish clinical ovarian cancer relapse. Randomized evidence did not demonstrate a survival advantage from starting chemotherapy solely at marker elevation rather than waiting for clinical relapse in the studied setting. A rising value therefore prompts assessment and discussion, not an automatic conclusion that immediate treatment extends life.
Apply it
An asymptomatic survivor has rising CA-125 without established structural recurrence. Review the trend, clinical findings and assessment options, then explain the difference between earlier detection and proven treatment benefit.
Common pitfall: The evidence does not justify ignoring symptoms or convincing radiographic recurrence. It also should not be interpreted as proving the marker has no informational value; the question is how that information changes management.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
Basic science applied to carenot stated
54.How does BRCA dysfunction impair homologous recombination?
BRCA1 and BRCA2 help repair DNA double-strand damage accurately through homologous recombination. Loss of effective function can force reliance on less accurate pathways, promoting genomic instability while creating treatment vulnerabilities. This helps explain platinum sensitivity in some BRCA-associated tumors. A sequence difference must nevertheless be classified appropriately before it is interpreted as a functional defect.
Apply it
A patient asks why BRCA-associated ovarian cancer may respond to platinum. Connect treatment-induced DNA damage with impaired accurate repair, while explaining that the biological rationale does not guarantee an individual response.
Common pitfall: All BRCA variants are not equivalent. Germline predisposition, tumor pathogenicity and the tumor's present repair capacity are related concepts but should not be treated as interchangeable findings.
55.Why can PARP inhibition produce synthetic lethality?
Synthetic lethality describes cell death caused by two combined defects when either alone may be tolerated. PARP inhibition disrupts DNA-damage handling and can trap PARP on DNA, creating replication-associated injury. Homologous-recombination-deficient cells have reduced capacity to repair the resulting damage. The interaction creates selective vulnerability rather than replacing defective BRCA protein or restoring accurate repair.
Apply it
Compare BRCA2-deficient cells with otherwise similar cells in which BRCA2 function is restored. Better survival after restoration supports the role of homologous recombination in resisting PARP-associated injury.
Common pitfall: Mechanistic plausibility does not establish an unrestricted clinical indication. Agent, disease setting, previous treatment and response still matter when translating synthetic lethality into a treatment decision.
56.How does bevacizumab inhibit tumor angiogenesis?
Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor and inhibits proangiogenic signaling. Its target is a pathway supporting blood-vessel formation. This differs from PARP inhibition, endocrine treatment and immune checkpoint blockade. Identifying the target helps organize mechanisms, but it does not establish that every angiogenic tumor or every patient will benefit from the drug.
Apply it
A patient asks whether bevacizumab repairs a BRCA defect. Explain that VEGF blockade addresses vessel-support signaling, whereas BRCA-associated treatment vulnerabilities concern DNA repair.
Common pitfall: Grouping all targeted therapies under one mechanism obscures meaningful differences. Bevacizumab does not directly restore tumor-suppressor function, inhibit PARP or release PD-1-mediated restraint on T cells.
57.How does PD-1 pathway blockade support antitumor immunity?
PD-1 on T cells can interact with PD-L1 to transmit an inhibitory signal. Some cancers exploit this pathway to evade immune attack. Blocking PD-1 or PD-L1 interrupts that inhibitory interaction and can strengthen antitumor activity. Removing immune restraint also explains inflammatory toxicity in normal organs. This mechanism differs from directly damaging DNA in dividing cells.
Apply it
A learner describes checkpoint blockade as suppressing T-cell function. Explain that the treatment removes a braking signal, linking its potential tumor benefit and immune-mediated adverse effects through the same biological action.
Common pitfall: PD-L1 expression does not universally guarantee response or define every indication. The absence of an immediate response also should not be interpreted as evidence that the drug's mechanism is direct cytotoxic chemotherapy.
58.How should a hereditary-cancer variant of uncertain significance be used?
A variant of uncertain significance lacks sufficient evidence for classification as pathogenic or benign. It should not independently justify irreversible risk-reducing surgery or be described as a confirmed hereditary-cancer diagnosis. Management follows established personal and family risk while classification may evolve. Finding a sequence difference does not itself demonstrate impaired function or increased cancer risk.
Apply it
An unaffected patient requests surgery solely because a BRCA2 report lists a VUS. Explain the classification and base risk counseling on the pedigree and established clinical factors.
Common pitfall: Calling a VUS a positive pathogenic result overstates knowledge. Calling it definitively benign is also inaccurate; the appropriate interpretation preserves uncertainty without allowing that uncertainty to become an unsupported indication.
59.Why is a negative familial-variant test more informative than an uninformative negative?
When a family has a documented pathogenic variant, a relative's negative test for that alteration can establish that it was not inherited. A negative panel in a family without an identified explanation may remain uninformative. Interpretation depends on the pedigree, who was tested and what the assay evaluated. Negative results therefore do not support one universal reassurance statement.
Apply it
Compare a patient negative for a known familial BRCA1 variant with a patient who has a strong unexplained pedigree and a negative panel. Explain why more hereditary uncertainty remains in the second situation.
Common pitfall: A true negative for one familial variant does not erase unrelated risk factors. An uninformative negative also cannot be presented as proof that no hereditary susceptibility exists in the family.
60.Why does brachytherapy produce concentrated local radiation exposure?
Brachytherapy positions a radiation source inside or close to the target. Dose decreases rapidly with increasing distance, permitting concentrated local exposure while limiting more distant tissue exposure. Source position and treatment time therefore strongly influence dose distribution. Nearby normal organs remain vulnerable because they can lie very close to the source, making geometry and planning clinically important.
Apply it
An applicator shifts despite an unchanged prescription. Explain that altered distances can change both target and organ exposure, so the same prescribed dose does not guarantee the same distribution.
Common pitfall: A localized source is not automatically harmless to adjacent tissues. Prescription dose alone cannot describe treatment quality without information about source placement, target coverage and normal-organ exposure.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Separate anatomical stage from prognostic and predictive information, particularly ovarian compartments, cervical nodal categories and trophoblastic stage versus score.
- Select treatment using histology, molecular findings, disease extent, prior treatment, physiological reserve and patient priorities.
- Rehearse surgical selection and contingencies, including complete ovarian cytoreduction, fertility preservation and failed vulvar sentinel mapping.
- Recognize anastomotic leak, postoperative hemorrhage and VTE; connect physiological stability to diagnostic testing, resuscitation and source control.
- Select ureteral reconstruction using injury location, viable tissue and the ability to create a tension-free repair.
- Distinguish tumor testing, germline testing, screening abnormalities, pathogenic variants and uncertain variants.
- Extend study through the full official outline, including uncommon tumors, additional operative injuries, critical care and placenta accreta spectrum.
A practical preparation plan
1. Map the complete competency outline
Create an inventory from all nine official domains and their task statements. Identify the objectives addressed here and schedule additional study for omitted operative, inpatient, rare-tumor and obstetric-hemorrhage content.
2. Reconstruct classifications
Explain ovarian IC and III–IV distinctions, cervical nodal categories, vaginal anatomical boundaries and trophoblastic stage versus score. Compare historical trophoblastic criteria with FIGO 2026, including qualifying imaging measurements, nodal notation and the 48-month PSTT/ETT boundary. Identify the decisive finding and the tempting finding that remains insufficient.
3. Practise treatment branches
For each case, state how invasion, histology, nodal status, biomarkers, fertility goals, prior irradiation, resectability and treatment tolerance change management.
4. Work the practice questions
Complete the 20 questions without notes. Explain the correct option and every alternative using the clinical findings. Treat errors as reasoning gaps rather than an estimate of examination performance.
5. Connect mechanisms to action
Use the flashcards to explain DNA repair, angiogenesis, immune inhibition, lymphatic injury and hCG surveillance. Rehearse initial care for unstable febrile neutropenia, suspected anastomotic leak, hemorrhage and postoperative pulmonary embolism, then select reconstruction for a defined ureteral injury.
6. Integrate the patient perspective
Present an assessment covering diagnosis, extent, treatment rationale, fertility, complications and survivorship. Include supportive care and the patient's priorities in the same clinical discussion.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABOG subspecialty-certification blueprint listing
- ABOG Gynecologic Oncology competency blueprint
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
- BRCA Gene Changes: Cancer Risk and Genetic Testing
- Genetics of Colorectal Cancer (PDQ)
- Endometrial Cancer Treatment (PDQ)
- Genetics of Breast and Gynecologic Cancers (PDQ)
- Endometrial Cancer Prevention (PDQ)
- Cervical Cancer Treatment (PDQ)
- Brachytherapy to Treat Cancer
- HPV and Cancer
- Vaginal Cancer Treatment (PDQ)
- Vulvar Cancer Treatment (PDQ)
- ESGO Pocket Guidelines: Vulvar Cancer — Update 2023
- Gestational Trophoblastic Disease Treatment (PDQ)
- Infection and Neutropenia and Cancer Treatment
- Nerve Problems (Peripheral Neuropathy) and Cancer Treatment
- Palliative Care in Cancer
- Lymphedema and Cancer
- BRCA1 and BRCA2 (PDQ)
- Bevacizumab
- Immune Checkpoint Inhibitors
- Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia | ACOG - College
- Placenta - CAP
- ASCO/IDSA Clinical Practice Guideline Update for Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
- outpatient-management-of-fever-and-neutropenia.pdf
- Gastrointestinal Complications (PDQ®) - NCI
- 208558Orig1s000MultidisciplineR.pdf
- 5.3 Management
- Olaparib - NCI
- 208558s031lbl.pdf
- Endometrial cancer guidelines | ESGO
- ctcae-v5-8x11.pdf
- ctcae-v6.pdf
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism - PMC
- EAU Guidelines on Urological Trauma - UROGENITAL TRAUMA GUIDELINES
- Using HPV tests for cervical cancer screening and managing HPV-positive women a practical online guide
- Pocket-Guidelines_Fertiliity-Sparing-in-Endometrial-Carcinoma.pdf
- 50-2-133.pdf
- 19894_vte-cancer-pocket-guide-8-panel_rev_high_res_proof.pdf
- European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023 - PMC
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.